SUSMED,Inc.

サスメド is a venture company seeking to address challenges in the healthcare sector, with digital therapeutics (DTx) using ICT as its core business. It comprises 2 segments: the DTx Product Business and the DTx Platform Business. The DTx Product Business is primarily engaged in developing and providing therapeutic applications. Insurance coverage for the insomnia disorder application Medcle® began on 1 June 2026, when sales also commenced. The DTx Platform Business provides a general-purpose clinical trial system and an automated machine-learning analysis system, as well as support for DTx development using these systems. As of June 2026, revenue was ¥340.234 million from the DTx Product Business and ¥156.977 million from the DTx Platform Business, for a total of ¥497.211 million. Research and development expenses were ¥247.459 million, total sales were unknown, operating loss was ¥330.161 million, ordinary loss was ¥325.530 million, and net loss was ¥382.691 million. Income from grants and other sources of ¥4.736 million was recorded as non-operating income. An impairment loss of ¥67.471 million was recorded as an extraordinary loss. Cash and cash equivalents at the end of the period were ¥3,698.300 million. The number of employees was 50, including the average number of temporary employees. The head office is located in 3-chome Nihonbashihoncho, Chuo-ku, Tokyo, and other locations are unknown. Major customers include KYORIN Pharmaceutical Co.,Ltd., Asuka Pharmaceutical Co., Ltd. and Shionogi & Co.,Ltd., among others. No regional sales data has been disclosed. In September 2021, the company conducted a stock split at a ratio of 700 common shares for each share, with figures calculated on a post-split basis from the beginning of the period, and was listed on the Tokyo Stock Exchange Mothers market in December 2021. In April 2022, it transferred from the Mothers market to the Growth market. In August 2024, it transitioned to a company with an audit and supervisory committee. In May 2026, it carried out a capital reduction and related measures. At the annual general meeting of shareholders held on 29 September 2026, Outside Director Akishima Yuko (秋嶋由子) ceased to serve as an outside director.